Semax vs IGF-1 LR3
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Semax
Semax is a synthetic peptide derived from ACTH (adrenocorticotropic hormone). Developed in Russia as a nootropic and neuroprotective agent.
Full details →IGF-1 LR3
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with extended half-life and enhanced potency. The modifications prevent binding to IGF binding proteins, increasing bioavailability.
Full details →Side-by-Side Comparison
| Aspect | Semax | IGF-1 LR3 |
|---|---|---|
| Mechanism | Enhances BDNF expression, modulates dopamine and serotonin systems, and provides neuroprotective effects. Increases attention, memory formation, and learning. | Binds to IGF-1 receptors to promote protein synthesis, muscle growth, and fat metabolism. The LR3 modification (13 amino acid extension and arginine substitution) extends half-life from minutes to 20-30 hours. |
| Typical Dosage | Intranasal: 200-600mcg 2-3 times daily. Higher doses (up to 1mg) used in clinical settings for stroke recovery. | Research protocols typically use 20-100mcg daily, often divided into multiple injections or administered bilaterally to target muscles. |
| Administration | Primarily administered intranasally. N-Acetyl Semax Amidate (NASA) is a modified version with enhanced stability and potency. | Intramuscular injection (site-specific growth) or subcutaneous for systemic effects. Often cycled 4-6 weeks on, equal time off. |
| Side Effects | Generally well-tolerated. May cause mild irritability or hair shedding in some users. | Hypoglycemia, joint pain, water retention, potential jaw/hand growth with extended use, and injection site reactions. |
| Best For |